Adjunctive cenobamate reduces seizure frequency in patients with uncontrolled focal seizures. A phase 2 randomised controlled trial of cenobomate at daily doses of 100 mg, 200 mg and 400 mg involved 437 patients from 107 epilepsy and neurology centres across 16 countries including Australia. Patients had a median age of 40 years, a seizure history ...
Cenobamate allows some patients to become seizure free
By Mardi Chapman
21 Nov 2019